What is Zacks Research’s Estimate for FMS Q4 Earnings?

Fresenius Medical Care AG (NYSE:FMS) – Investment analysts at Zacks Research dropped their Q4 2024 earnings per share estimates for Fresenius Medical Care in a research report issued to clients and investors on Monday, December 30th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will post earnings per share of $0.38 for the quarter, down from their prior forecast of $0.39. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.55 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q1 2025 earnings at $0.39 EPS, Q2 2025 earnings at $0.42 EPS, Q3 2025 earnings at $0.53 EPS, Q4 2025 earnings at $0.54 EPS, FY2025 earnings at $1.87 EPS, Q1 2026 earnings at $0.46 EPS, Q2 2026 earnings at $0.47 EPS, Q3 2026 earnings at $0.59 EPS and FY2026 earnings at $2.13 EPS.

Several other brokerages have also recently issued reports on FMS. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price for the company. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Truist Financial lifted their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Finally, StockNews.com initiated coverage on Fresenius Medical Care in a research report on Thursday, November 28th. They issued a “strong-buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $24.30.

Fresenius Medical Care Stock Performance

Shares of FMS opened at $22.64 on Wednesday. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care has a 52-week low of $17.93 and a 52-week high of $24.31. The stock has a 50 day moving average price of $22.19 and a 200 day moving average price of $20.63. The company has a market capitalization of $13.29 billion, a price-to-earnings ratio of 18.71, a price-to-earnings-growth ratio of 0.96 and a beta of 0.93.

Hedge Funds Weigh In On Fresenius Medical Care

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Allworth Financial LP raised its position in Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after buying an additional 581 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Fresenius Medical Care during the third quarter worth about $38,000. GAMMA Investing LLC raised its holdings in Fresenius Medical Care by 50.4% during the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after purchasing an additional 1,675 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in Fresenius Medical Care in the third quarter valued at about $112,000. Finally, Venturi Wealth Management LLC boosted its holdings in Fresenius Medical Care by 1,045.8% in the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after purchasing an additional 4,800 shares in the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.